---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138948"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:43:44.036988+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q1 net loss $12.8M vs $7.2M YoY; cash $159.5M; FDA Fast Track for ACR-368

## Summary
- Net loss $12.8M for Q1 2023, widened from $7.2M in Q1 2022; R&D expense $9.8M (up from $6.1M).
- Cash, equivalents and marketable securities $159.5M as of March 31, 2023; runway into Q4 2024.
- FDA granted Fast Track designation for ACR-368 monotherapy in OncoSignature-positive platinum-resistant ovarian and endometrial cancer.
- Phase 2 registrational trial of ACR-368 continues enrolling; initial clinical readouts expected H2 2023.
- Advancing WEE1 and PKMYT1 inhibitor programs toward IND-enabling studies in 2023.

## SEC filing metadata
- accession: 0001193125-23-138948
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523138948/0001193125-23-138948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523138948/d421791d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138948
- JSON: https://secwatch.observer/filing/0001193125-23-138948.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138948.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $12.8 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $12.8 million
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023 was $12.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523138948/0001193125-23-138948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.